Founding shareholder and CEO. Dr Wilson developed the platform and took the product through clinical trials in competition with Googles' Verily Contact Lens. Demonstrated the first clinical application of the sensor in human diabetic patients. Oversaw complete development in accordance with ISO 13485 including ASIC development , sensor validation, pre-clinical and clinical trials.
EXITED 2020 to Private Equity
On behalf of the shareholders of the company advised the management on reshaping and refocusing the business strategy and relaunching in an ongoing change management process and advised on the exit to a strategic party in The Netherlands.
EXITED 2020 to Strategic Party
Co-developed and directed the HUB masterclass together with WhaleBay & Co. Sponsored by the Province of Zuid Holland and The City of Rotterdam. Supporting entrepreneurs in preparation for global market entry. Worked with selected group of companies in a six month intensive program of coaching and mentoring culminating in bringing these companies to the USA.
Partnership Zuid Holland and Gemeente Rotterdam
After a successful HUB program LLS took over the commercial directors position acting operationally to build the company securing Series A financing in July 2022. Developed commercial strategy, key accounts and partners.
Series A July 2022 - Operational Services Ongoing
Business development and global market entry strategy later transitioning into operational role as Clinical Director. Ongoing growth and continued clinical excellence of the company following CE Mark
Advisory and Operational Services Ongoing
Listerdale LifeSciences BV provides expert subject matter advisory services in the life sciences and health industry on an ongoing basis to a number of investment and advisory companies.
Advisory Services Ongoing
Developed applications of a novel hydrogel material. Advising and providing expert subject matter assistance to Radboud University and University Medical Centre Nijmegen we identified and secured valuable IP rights in the application domains of cell growth and regenerative medicine
Established Spinout Companies 2015
Supported the investors and management team in transitional activities and strategic planning. Facilitated contact with strategic parties and clinical and technical validation plan.
Asset Divestment 2022
We represented the parent company providing expert guidance on regulatory and product development strategy along with drafting of the business plan and financial planning as well as working with first customers to determine product specifications
Spun out from parent company 2016
Listerdale Life Sciences provided management board services representing the shareholders of NovioSpin BV. We engaged with the CEO in developing the business plan, R&D and product development plan along with long term strategy advice.
Project 2017
Listerdale Life Sciences assisted the CEO and COO of NovioCell in the development of its product portfolio in the ideation phase exploring potential application areas of its hydrogel technology
Project 2016
Founder of NovioTech incubator, working together with universities and first time entrepreneurs to develop cutting edge life science innovation.
Divested 2020
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.